SEARCH:   Advanced

Blood, 8 January 2009, Vol. 113, No. 2, pp. 273-278. Prepublished online as a Blood First Edition Paper on October 2, 2008; DOI 10.1182/blood-2008-07-167098. This Article Full Text Full Text (PDF) Supplemental Methods, Tables, and Figures All Versions of this Article: blood-2008-07-167098v1 113/2/273    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Paczesny, S. Articles by Ferrara, J. L. M. Search for Related Content PubMed PubMed Citation Articles by Paczesny, S. Articles by Ferrara, J. L. M. Related Collections Transplantation Plenary Papers Free Research Articles Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  PLENARY PAPER A biomarker panel for acute graft-versus-host disease Sophie Paczesny1,2,*, Oleg I. Krijanovski3,*, Thomas M. Braun4, Sung W. Choi1,3, Shawn G. Clouthier1, Rork Kuick5, David E. Misek6, Kenneth R. Cooke7, Carrie L. Kitko1,3, Angela Weyand1, Daniel Bickley1, Dawn Jones1,3, Joel Whitfield1,3, Pavan Reddy3, John E. Levine1,3, Samir M. Hanash2, and James L. M. Ferrara1,3 1 Department of Pediatrics, University of Michigan, Ann Arbor; 2 Fred Hutchinson Cancer Research Center, Seattle, WA; 3 Department of Internal Medicine, 4 Department of Biostatistics, 5 Comprehensive Cancer Center Biostatistics Core, and 6 Department of Surgery, University of Michigan, Ann Arbor; and 7 Department of Pediatrics, Case Western Reserve University, Cleveland, OH No validated biomarkers exist for acute graft-versus-host disease (GVHD). We screened plasma with antibody microarrays for 120 proteins in a discovery set of 42 patients who underwent transplantation that revealed 8 potential biomarkers for diagnostic of GVHD. We then measured by enzyme-linked immunosorbent assay (ELISA) the levels of these biomarkers in samples from 424 patients who underwent transplantation randomly divided into training (n = 282) and validation (n = 142) sets. Logistic regression analysis of these 8 proteins determined a composite biomarker panel of 4 proteins (interleukin-2-receptor-alpha, tumor-necrosis-factor-receptor-1, interleukin-8, and hepatocyte growth factor) that optimally discriminated patients with and without GVHD. The area under the receiver operating characteristic curve distinguishing these 2 groups in the training set was 0.91 (95% confidence interval, 0.87–0.94) and 0.86 (95% confidence interval, 0.79–0.92) in the validation set. In patients with GVHD, Cox regression analysis revealed that the biomarker panel predicted survival independently of GVHD severity. A panel of 4 biomarkers can confirm the diagnosis of GVHD in patients at onset of clinical symptoms of GVHD and provide prognostic information independent of GVHD severity. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Graft-versus-host disease: proteomics comes of age Gerard Socié Blood 2009 113: 271-272. [Full Text] [PDF] This article has been cited by other articles: G. Socie and B. R. Blazar Acute graft-versus-host disease: from the bench to the bedside Blood, November 12, 2009; 114(20): 4327 - 4336. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020